| |
|
|
|
|
|
|
|||
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2744-2749. Prepublished online as a Blood First Edition Paper on July 12, 2005; DOI 10.1182/blood-2005-04-1454.
Submitted April 8, 2005
Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experiemental Medicine, The Scripps Research Institute, La Jolla, CA, USA * Corresponding author; email: tomk{at}scripps.edu.
Using recombinant human GPVI, we evaluated the effect of N-linked glycosylation at the consensus site N92GS94 on binding of this platelet-specific receptor to its ligands, human type I collagen, collagen-related peptide (CRP) and the snake venom C-type lectin convulxin (CVX). In COS-7 cells transiently transfected with GPVI, deglycosylation with PNGase F (specific for complex N-linked glycans) or tunicamycin decreases the molecular weight of GPVI and reduces transfected COS-7 cell binding to both CRP and CVX. In stably transfected Dami cells, the substitutions N92A or S94A, but not L95H, resulted in a 30-40% decrease in adhesion to CVX, but a 90% or greater decrease in adhesion to CRP and a 65-70% decrease in adhesion to type I collagen. Treatment with PNGase F, but not Endo H (specific for high-mannose N-linked glycans), produced an equivalent decrease in molecular weight. Neither N92A nor S94A affected the expression of GPVI, based on the direct binding of murine anti-human GPVI monoclonal antibody 204-11 to transfected Dami cells. These findings indicate that N-linked glycosylation at N92 in human GPVI is not required for surface expression, but contributes to maximal adhesion to type I collagen, CRP and, to a lesser extent, CVX
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||